Inspire Investing LLC Has $410,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Inspire Investing LLC raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 23.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,308 shares of the company’s stock after buying an additional 4,018 shares during the quarter. Inspire Investing LLC’s holdings in Syndax Pharmaceuticals were worth $410,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $27,000. nVerses Capital LLC bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $33,000. Quarry LP grew its stake in shares of Syndax Pharmaceuticals by 75.0% in the 2nd quarter. Quarry LP now owns 6,125 shares of the company’s stock valued at $126,000 after buying an additional 2,625 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Syndax Pharmaceuticals by 28.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock valued at $171,000 after buying an additional 1,587 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in Syndax Pharmaceuticals by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after acquiring an additional 1,312 shares in the last quarter.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $19.71 on Friday. The stock has a fifty day moving average price of $19.33 and a 200-day moving average price of $20.59. The firm has a market cap of $1.68 billion, a PE ratio of -5.83 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The company had revenue of $3.50 million during the quarter. During the same quarter last year, the firm posted ($0.64) EPS. The firm’s revenue was up 3499999990.0% on a year-over-year basis. As a group, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNDX has been the subject of several recent research reports. Citigroup boosted their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. dropped their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus boosted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Jefferies Financial Group started coverage on Syndax Pharmaceuticals in a report on Friday, June 28th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, Bank of America upped their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.78.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).